PRODUCT INFORMATION

Sermorelin (acetate)

Item No. 36696

CAS Registry No.: 516482-86-3
Formal Name: 29-L-argininamide-1-29-somatoliberin (human pancreatic islet), acetate
Synonyms: Growth Hormone-releasing Factor (1-29) amide, hGH-RH(1-29)-NH2, hGRF(1-29)NH2, hpGRF(1-29)NH2, Somatotropin Releasing-Hormone (1-29) amide
MF: $C_{149}H_{246}N_{44}O_{42}S \bullet XC_2H_4O_2$
FW: 3,357.9
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Sermorelin (acetate) is supplied as a solid. A stock solution may be made by dissolving the sermorelin (acetate) in water. The solubility of sermorelin (acetate) in water is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Sermorelin is a 29-residue N-terminal analog of growth hormone-releasing hormone (GHRH) that retains the ability to stimulate growth hormone (GH) release.[1] Sermorelin (1 µg/kg, i.v.) increases serum GH levels in rats by approximately 17% compared with saline control after 15 minutes.[2] It also increases GH release in pigs when administered at a dose of 250 ng/kg.[3] Sermorelin (1 µM) increases proliferation of NCI-H727 human bronchial carcinoid cells by 30% and increases vascular endothelial growth factor (VEGF) secretion.[4] It increases phosphorylation of focal adhesion kinase (FAK) and expression of VEGF in A549 lung cancer cells when used at a concentration of 0.1 µM.[5] Formulations containing sermorelin have been used to diagnose and treat growth hormone deficiency.

References

1. Rivier, J., Spiess, J., Thorner, M., *et al.* Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. *Nature* **300(5889)**, 276-278 (1982).
2. Izdebski, J., Pinski, J., Horvath, J.E., *et al.* Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. *Proc. Natl. Acad. Sci. USA* **92(11)**, 4872-4876 (1995).
3. Lance, V.A., Murphy, W.A., Sueiras-Diaz, J., *et al.* Super-active analogs of growth hormone-releasing factor (1-29)-amide. *Biochem. Bioph. Res. Commun.* **119(1)**, 265-272 (1984).
4. Stepień, T., Sacewicz, M., Lawnicka, H., *et al.* Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 *in vitro*. *Neuropeptides* **43(5)**, 397-400 (2009).
5. Siejka, A., Barabutis, N., and Schally, A.V. GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells *in vitro*. *Peptides* **37(1)**, 63-68 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM